BioMarin Pharmaceutical Inc. (0HNC.L)
USD 58.91
(-5.27%)
USD 58.91
(-5.27%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 6.84 Billion USD | 7.32% |
| 2022 | 6.37 Billion USD | 6.19% |
| 2021 | 6 Billion USD | 2.66% |
| 2020 | 5.84 Billion USD | 24.69% |
| 2019 | 4.69 Billion USD | 5.94% |
| 2018 | 4.42 Billion USD | -4.45% |
| 2017 | 4.63 Billion USD | 15.15% |
| 2016 | 4.02 Billion USD | 7.89% |
| 2015 | 3.72 Billion USD | 49.75% |
| 2014 | 2.49 Billion USD | 10.73% |
| 2013 | 2.24 Billion USD | 40.43% |
| 2012 | 1.6 Billion USD | 22.86% |
| 2011 | 1.3 Billion USD | 3.25% |
| 2010 | 1.26 Billion USD | 37.67% |
| 2009 | 917.16 Million USD | 1.15% |
| 2008 | 906.69 Million USD | 11.21% |
| 2007 | 815.27 Million USD | 75.92% |
| 2006 | 463.43 Million USD | 137.29% |
| 2005 | 195.3 Million USD | -16.17% |
| 2004 | 232.96 Million USD | -9.12% |
| 2003 | 256.34 Million USD | 131.74% |
| 2002 | 110.61 Million USD | -35.62% |
| 2001 | 171.81 Million USD | 123.33% |
| 2000 | 76.93 Million USD | -25.7% |
| 1999 | 103.54 Million USD | 228.73% |
| 1998 | 31.5 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 6.87 Billion USD | 0.45% |
| 2024 Q2 | 7.06 Billion USD | 2.83% |
| 2024 Q3 | 6851.19 Billion USD | -3.06% |
| 2023 Q3 | 6.75 Billion USD | 2.97% |
| 2023 FY | 6.84 Billion USD | 7.32% |
| 2023 Q4 | 6.84 Billion USD | 1.23% |
| 2023 Q1 | 6.43 Billion USD | 0.92% |
| 2023 Q2 | 6.56 Billion USD | 2.01% |
| 2022 Q4 | 6.37 Billion USD | 1.77% |
| 2022 Q3 | 6.26 Billion USD | 1.92% |
| 2022 FY | 6.37 Billion USD | 6.19% |
| 2022 Q1 | 6.06 Billion USD | 0.99% |
| 2022 Q2 | 6.14 Billion USD | 1.37% |
| 2021 Q3 | 5.97 Billion USD | 1.34% |
| 2021 Q4 | 6 Billion USD | 0.43% |
| 2021 FY | 6 Billion USD | 2.66% |
| 2021 Q1 | 5.8 Billion USD | -0.73% |
| 2021 Q2 | 5.89 Billion USD | 1.61% |
| 2020 FY | 5.84 Billion USD | 24.69% |
| 2020 Q3 | 6.15 Billion USD | 16.14% |
| 2020 Q1 | 4.72 Billion USD | 0.7% |
| 2020 Q2 | 5.3 Billion USD | 12.27% |
| 2020 Q4 | 5.84 Billion USD | -5.04% |
| 2019 Q3 | 4.55 Billion USD | 3.75% |
| 2019 FY | 4.69 Billion USD | 5.94% |
| 2019 Q1 | 4.43 Billion USD | 0.19% |
| 2019 Q2 | 4.39 Billion USD | -0.95% |
| 2019 Q4 | 4.69 Billion USD | 2.89% |
| 2018 Q1 | 4.59 Billion USD | -0.79% |
| 2018 FY | 4.42 Billion USD | -4.45% |
| 2018 Q4 | 4.42 Billion USD | -5.71% |
| 2018 Q3 | 4.69 Billion USD | 1.53% |
| 2018 Q2 | 4.62 Billion USD | 0.61% |
| 2017 Q3 | 4.58 Billion USD | 13.95% |
| 2017 Q1 | 3.93 Billion USD | -2.11% |
| 2017 FY | 4.63 Billion USD | 15.15% |
| 2017 Q2 | 4.01 Billion USD | 2.07% |
| 2017 Q4 | 4.63 Billion USD | 1.14% |
| 2016 Q1 | 3.66 Billion USD | -1.67% |
| 2016 Q4 | 4.02 Billion USD | 4.72% |
| 2016 FY | 4.02 Billion USD | 7.89% |
| 2016 Q3 | 3.84 Billion USD | 24.45% |
| 2016 Q2 | 3.08 Billion USD | -15.81% |
| 2015 Q1 | 3.65 Billion USD | 46.91% |
| 2015 Q2 | 3.64 Billion USD | -0.27% |
| 2015 Q4 | 3.72 Billion USD | 2.88% |
| 2015 FY | 3.72 Billion USD | 49.75% |
| 2015 Q3 | 3.62 Billion USD | -0.65% |
| 2014 Q2 | 2.34 Billion USD | 0.21% |
| 2014 FY | 2.49 Billion USD | 10.73% |
| 2014 Q3 | 2.44 Billion USD | 4.04% |
| 2014 Q4 | 2.49 Billion USD | 2.05% |
| 2014 Q1 | 2.34 Billion USD | 4.07% |
| 2013 Q3 | 1.62 Billion USD | 1.19% |
| 2013 Q1 | 1.59 Billion USD | -0.21% |
| 2013 Q2 | 1.6 Billion USD | 0.2% |
| 2013 FY | 2.24 Billion USD | 40.43% |
| 2013 Q4 | 2.24 Billion USD | 38.8% |
| 2012 FY | 1.6 Billion USD | 22.86% |
| 2012 Q4 | 1.6 Billion USD | 2.19% |
| 2012 Q1 | 1.29 Billion USD | -0.51% |
| 2012 Q2 | 1.53 Billion USD | 18.15% |
| 2012 Q3 | 1.56 Billion USD | 2.27% |
| 2011 Q4 | 1.3 Billion USD | 0.66% |
| 2011 FY | 1.3 Billion USD | 3.25% |
| 2011 Q3 | 1.29 Billion USD | 1.15% |
| 2011 Q1 | 1.26 Billion USD | 0.12% |
| 2011 Q2 | 1.28 Billion USD | 1.29% |
| 2010 Q3 | 1.24 Billion USD | 26.28% |
| 2010 FY | 1.26 Billion USD | 37.67% |
| 2010 Q2 | 985.51 Million USD | 2.0% |
| 2010 Q1 | 966.2 Million USD | 5.35% |
| 2010 Q4 | 1.26 Billion USD | 1.45% |
| 2009 Q4 | 917.16 Million USD | 5.5% |
| 2009 FY | 917.16 Million USD | 1.15% |
| 2009 Q1 | 900.28 Million USD | -0.71% |
| 2009 Q2 | 844.43 Million USD | -6.2% |
| 2009 Q3 | 869.35 Million USD | 2.95% |
| 2008 Q4 | 906.69 Million USD | 5.55% |
| 2008 Q3 | 859.03 Million USD | 0.52% |
| 2008 Q1 | 827.7 Million USD | 1.52% |
| 2008 Q2 | 854.55 Million USD | 3.24% |
| 2008 FY | 906.69 Million USD | 11.21% |
| 2007 FY | 815.27 Million USD | 75.92% |
| 2007 Q1 | 449.76 Million USD | -2.95% |
| 2007 Q2 | 781.63 Million USD | 73.79% |
| 2007 Q3 | 791.05 Million USD | 1.2% |
| 2007 Q4 | 815.27 Million USD | 3.06% |
| 2006 Q2 | 468.71 Million USD | -4.0% |
| 2006 Q3 | 467.07 Million USD | -0.35% |
| 2006 Q1 | 488.22 Million USD | 149.99% |
| 2006 FY | 463.43 Million USD | 137.29% |
| 2006 Q4 | 463.43 Million USD | -0.78% |
| 2005 FY | 195.3 Million USD | -16.17% |
| 2005 Q3 | 208.84 Million USD | 24.87% |
| 2005 Q2 | 167.24 Million USD | -7.56% |
| 2005 Q1 | 180.93 Million USD | -22.34% |
| 2005 Q4 | 195.3 Million USD | -6.48% |
| 2004 FY | 232.96 Million USD | -9.12% |
| 2004 Q1 | 239.29 Million USD | -6.65% |
| 2004 Q2 | 347.41 Million USD | 45.18% |
| 2004 Q3 | 312.23 Million USD | -10.13% |
| 2004 Q4 | 232.96 Million USD | -25.39% |
| 2003 Q4 | 256.34 Million USD | -9.88% |
| 2003 Q3 | 284.44 Million USD | -7.16% |
| 2003 Q2 | 306.38 Million USD | 67.32% |
| 2003 Q1 | 183.11 Million USD | 65.54% |
| 2003 FY | 256.34 Million USD | 131.74% |
| 2002 Q1 | 157.3 Million USD | -8.44% |
| 2002 FY | 110.61 Million USD | -35.62% |
| 2002 Q4 | 110.61 Million USD | -13.22% |
| 2002 Q2 | 141.97 Million USD | -9.75% |
| 2002 Q3 | 127.46 Million USD | -10.22% |
| 2001 Q4 | 171.81 Million USD | 90.05% |
| 2001 Q2 | 98.32 Million USD | 50.24% |
| 2001 Q1 | 65.44 Million USD | -14.94% |
| 2001 Q3 | 90.4 Million USD | -8.05% |
| 2001 FY | 171.81 Million USD | 123.33% |
| 2000 Q2 | 86.09 Million USD | -8.89% |
| 2000 Q3 | 83.32 Million USD | -3.21% |
| 2000 FY | 76.93 Million USD | -25.7% |
| 2000 Q1 | 94.49 Million USD | -8.75% |
| 2000 Q4 | 76.93 Million USD | -7.67% |
| 1999 Q3 | 112.5 Million USD | 118.87% |
| 1999 Q2 | 51.4 Million USD | 91.79% |
| 1999 Q1 | 26.8 Million USD | 0.0% |
| 1999 FY | 103.54 Million USD | 228.73% |
| 1999 Q4 | 103.54 Million USD | -7.96% |
| 1998 FY | 31.5 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | -722.616% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -630.068% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -779.519% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -4033.799% |
| bluebird bio, Inc. | 619.16 Million USD | -1004.98% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -5336.575% |
| Imunon, Inc. | 21.91 Million USD | -31114.442% |
| Editas Medicine, Inc. | 499.15 Million USD | -1270.642% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 74.358% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | -103.889% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -470.752% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | -110.42% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | -385.572% |
| Verastem, Inc. | 149.71 Million USD | -4469.66% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 91.557% |
| Waters Corporation | 4.62 Billion USD | -47.867% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 93.07% |
| Biogen Inc. | 26.84 Billion USD | 74.514% |
| Nektar Therapeutics | 398.03 Million USD | -1618.853% |
| Perrigo Company plc | 10.8 Billion USD | 36.705% |
| Dynavax Technologies Corporation | 997.09 Million USD | -586.153% |
| Illumina, Inc. | 10.11 Billion USD | 32.335% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -24098.882% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -776.734% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -2974.795% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -10314.984% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -4038.4% |
| Evolus, Inc. | 188.99 Million USD | -3519.934% |
| Adicet Bio, Inc. | 207.29 Million USD | -3200.419% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -3365.77% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 79.318% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -3224.459% |
| FibroGen, Inc. | 423.52 Million USD | -1515.38% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 36.434% |
| OPKO Health, Inc. | 2.01 Billion USD | -240.091% |
| Homology Medicines, Inc. | 47.05 Million USD | -14438.97% |
| Geron Corporation | 394.07 Million USD | -1636.113% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | -78.638% |
| Exelixis, Inc. | 2.94 Billion USD | -132.521% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -1756.659% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -4331.492% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | -425.882% |
| Zoetis Inc. | 14.28 Billion USD | 52.11% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -1063.071% |
| Abeona Therapeutics Inc. | 64 Million USD | -10589.671% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 69.901% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -12128.285% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | -128.811% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | -109.571% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -1000.791% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | -294.722% |
| Blueprint Medicines Corporation | 1.04 Billion USD | -552.047% |
| Insmed Incorporated | 1.32 Billion USD | -414.469% |
| TG Therapeutics, Inc. | 329.58 Million USD | -1975.811% |
| Incyte Corporation | 6.78 Billion USD | -0.877% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | -272.86% |